This included a trend towards reduced numbers of dermal inflammatory cells (i.e. CD3+, CD11c+ and MPO+ cells) and a return of the resident Langerhans cells (observed as CD1a+ cells) in the six subjects with psoriasis treated with seletalisib 15 mg relative to the three placebo-treated subjects with psoriasis (Fig. 3). Here, MPO is linked to psoriasis.